Humaid Al-Shamsi, The Chairman of Nexomic, CEO of Burjeel Cancer Institute (BCI) Comprehensive Cancer Center, shared a post on LinkedIn:
“Proud to share a major scientific milestone for Nexomic.
5 abstracts have been accepted for presentation at European Society for Medical Oncology Congress 2026 in Madrid, 23–27 October.
The studies showcase our latest innovations in AI-driven precision oncology.
Accepted abstracts:
#2737: A Self-supervised Multi-omic AI Foundation Model Recovers Prognostic Subgroups Across Seven Independent Solid Tumour Cohorts
#7878: A Pretrained Multi-omic AI Foundation Model Identifies Eight Prognostically Distinct Breast Cancer Subgroups in METABRIC
#7766: Pathway-guided Multi-omic AI Reconstructs Missing RNA and DNA Methylation Profiles Across 34 Cancer Types
#7824: DNA-only Multi-omic AI Identifies Tumour Primary Site Across 31 Lineages for Cancer of Unknown Primary
#7967: Multi-omic AI Stratifies Survival in Immunotherapy-treated Metastatic Pancreatic Cancer.
This milestone reflects the dedication of Nexomic’s multidisciplinary team and our mission to transform complex multi-omic data into meaningful insights.
Excited to share our work with the global oncology community at ESMO 2026.”
Other posts featuring Humaid Al-Shamsi on OncoDaily.